News Sanofi pledges a $20 billion investment programme in the US Sanofi is the latest European pharma group to promise a big capital investment programme on manufacturing and R&D in the US.
R&D Q1 Clinical trials round-up: Jan-Mar 2025 The first quarter of 2025 saw a wave of significant advancements in clinical research across oncology, neurology, dermatology, respiratory, and rare diseases.
News Gilead ups its US investment plans by $11 billion Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US.
News EU joins the bid to court beleaguered US scientists The EU has announced a €500m scheme to convince scientific talent from around the world to relocate to Europe's "free and open" research environment.
News Can other countries entice US scientists hit by Trump cuts? The UK is said to be preparing a £50m scheme to attract top scientific talent from other countries, including US teams facing big funding cuts.
News Trump's budget would be "catastrophic" for federal R&D Trump's 2026 budget request envisages sweeping cuts to funding for the NIH and other federal agencies that will be a disaster, say science advocates.
R&D LSX2026: On a therapeutic vision for ocular disease, with Al... Alexander Gebauer, co-founder & executive chairman of Galimedix Therapeutics, discusses transforming treatment of major neurodegenerative eye diseases
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
